Abstract: A hybrid electric vehicle charging station (EVCS) is provided. The EVCS includes a charging chassis that is configured to support a charging circuitry for providing a charge current to an electric vehicle and a multi-conductor cable that is attached to the charging chassis and that receives the charging current from the charging circuitry and that transmits the charging current to the electric vehicle. The EVCS further includes a user interface that is attached to the charging chassis and that is configured to provide digital content to a vehicle operator during a charging event of the electric vehicle. The charging chassis includes multiple user interface attachment structures that are each configured to support the user interface.

Abstract: Compound (I), and pharmaceutically acceptable salts thereof, are inducers of human interferon. Certain discrete and particular dosages of Compound (I) may be particularly useful in the treatment of various disorders, for example the treatment of allergic diseases and other inflammatory conditions, for example allergic rhinitis and allergic asthma.

Abstract: Compound (I), and pharmaceutically acceptable salts thereof, are inducers of human interferon. Certain discrete and particular dosages of Compound (I) may be particularly useful in the treatment of various disorders, for example the treatment of allergic diseases and other inflammatory conditions, for example allergic rhinitis and allergic asthma.

Abstract: Compound (I), and pharmaceutically acceptable salts thereof, are inducers of human interferon. Certain discrete and particular dosages of Compound (I) may be particularly useful in the treatment of various disorders, for example the treatment of allergic diseases and other inflammatory conditions, for example allergic rhinitis and allergic asthma.